TALK trades 0.8% below Wall Street's consensus target of $5.25.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TALK achieves its forward estimates and maintains a stable P/E multiple of 38.6x. This scenario reflects the blended consensus of 10 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 21, 2026, Talkspace, Inc. (TALK) has a Wall Street consensus price target of $5.25, based on estimates from 10 covering analysts. With the stock currently trading at $5.21, this represents a potential upside of +0.8%. The company has a market capitalization of $873M.
Analyst price targets range from a low of $5.25 to a high of $5.25, representing a 0% spread in expectations. The median target of $5.25 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 2 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, TALK trades at a trailing P/E of 130.3x and forward P/E of 38.6x.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
OPRXOptimizeRx Corporation | $93M | $4.98 | $17.00 | +241.4% | Buy | 5.3x | 15 |
ACMRACM Research, Inc. | $7.3B | $109.87 | $100.00 | -9.0% | Buy | 55.2x | 10 |
MNMDMind Medicine (MindMed) Inc. | $2.0B | $20.69 | $20.00 | -3.3% | Buy | — | 1 |
CLOVClover Health Investments, Corp. | $2.6B | $5.00 | $4.47 | -10.6% | Hold | 129.2x | 9 |
DOCSDoximity, Inc. | $3.8B | $20.46 | $29.47 | +44.0% | Hold | 14.3x | 23 |
TDOCTeladoc Health, Inc. | $1.5B | $8.07 | $7.40 | -8.3% | Hold | — | 42 |
AMWLAmerican Well Corporation | $141M | $8.43 | $6.33 | -24.9% | Hold | — | 15 |
HIMSHims & Hers Health, Inc. | $7.8B | $35.47 | $28.08 | -20.8% | Hold | — | 20 |
GDRXGoodRx Holdings, Inc. | $922M | $2.66 | $3.08 | +15.8% | Hold | 8.6x | 24 |
UNHUnitedHealth Group Incorporated | $363.9B | $400.96 | $425.81 | +6.2% | Buy | 21.8x | 52 |
Quick answers to the most common questions about buying TALK stock.
The consensus price target for TALK is $5.25, close to the current price of $5.21 (0.8% implied move). Based on 10 analyst estimates, the stock appears fairly valued near current levels.
TALK has a consensus rating of "Hold" based on 10 Wall Street analysts. The rating breakdown is mixed, with 8 Hold ratings making up the largest segment. The consensus 12-month price target of $5.25 implies 0.8% upside from current levels.
At a forward P/E of 38.5926x, TALK trades at a premium valuation. The consensus price target of $5.25 (0.8% upside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $5.25 for TALK, while the most conservative target is $5.25. The consensus of $5.25 represents the median expectation. These targets typically reflect 12-month expectations.
TALK is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 8 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TALK stock forecast based on 10 Wall Street analysts shows a consensus price target of $5.25, with estimates ranging from $5.25 (bear case) to $5.25 (bull case). The median consensus rating is "Hold".
TALK trades at a forward P/E ratio of 38.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 130.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
TALK appears fairly valued according to analysts, with a "Hold" rating and minimal upside to the $5.25 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TALK analyst price targets range from $5.25 to $5.25, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5.25 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.